Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen lowered shares of Mineralys Therapeutics (NASDAQ:MLYS) from a sell rating to a strong sell rating in a report issued on Saturday morning.

MLYS has been the topic of a number of other reports. Jefferies Financial Group reaffirmed a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. TD Cowen initiated coverage on shares of Mineralys Therapeutics in a research report on Monday, April 27th. They set a “buy” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $49.33.

Mineralys Therapeutics Stock Down 1.7%

Shares of NASDAQ:MLYS opened at $25.64 on Friday. The company has a quick ratio of 44.33, a current ratio of 34.46 and a debt-to-equity ratio of 0.18. The business has a fifty day moving average of $26.48 and a two-hundred day moving average of $27.54. The stock has a market cap of $2.27 billion, a P/E ratio of -6.05 and a beta of 0.68. Mineralys Therapeutics has a 52-week low of $14.16 and a 52-week high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) EPS for the quarter, missing the consensus estimate of ($0.55) by ($2.30). On average, research analysts expect that Mineralys Therapeutics will post -4.46 earnings per share for the current year.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, CEO Jon Congleton sold 75,000 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total transaction of $1,960,500.00. Following the completion of the transaction, the chief executive officer owned 614,321 shares of the company’s stock, valued at $16,058,350.94. This trade represents a 10.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of Mineralys Therapeutics stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $25.00, for a total transaction of $75,000.00. Following the sale, the director owned 6,200 shares of the company’s stock, valued at approximately $155,000. This represents a 32.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 217,313 shares of company stock worth $5,624,488. 18.94% of the stock is owned by corporate insiders.

Institutional Trading of Mineralys Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Navalign LLC purchased a new position in shares of Mineralys Therapeutics during the fourth quarter worth $33,000. KBC Group NV acquired a new stake in shares of Mineralys Therapeutics in the first quarter valued at $33,000. Royal Bank of Canada raised its holdings in shares of Mineralys Therapeutics by 262.3% in the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after buying an additional 1,107 shares during the period. FNY Investment Advisers LLC raised its holdings in shares of Mineralys Therapeutics by 400.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company’s stock valued at $67,000 after buying an additional 2,000 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Mineralys Therapeutics by 1,845.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock worth $76,000 after acquiring an additional 1,993 shares in the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.

Mineralys Therapeutics News Summary

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Near-term estimates improved: HC Wainwright raised its Q3 2026 EPS estimate to a loss of $0.56 from $0.61 and its Q4 estimate to a loss of $0.60 from $0.70. The firm maintained its Buy rating, indicating continued confidence in Mineralys’ prospects. Mineralys Therapeutics analyst coverage
• Positive Sentiment: Regulatory catalyst remains intact: Mineralys reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational hypertension treatment, and said launch preparations are advancing. Approval could provide the company with its first commercial opportunity. Mineralys second-quarter results and corporate update
• Positive Sentiment: Cash runway and leadership support the launch plan: Management said its funding should support operations into 2028, while the appointment of Dr. Terry Ferguson as chief medical officer adds cardiovascular-development expertise ahead of a potential launch.
• Neutral Sentiment: Inducement awards granted to new CMO: Mineralys authorized options covering 135,000 shares and restricted stock units covering 102,400 shares for Dr. Ferguson. The awards help recruit key leadership but could modestly increase future share dilution. Mineralys inducement award announcement
• Negative Sentiment: Large quarterly earnings miss: Mineralys reported a second-quarter loss of $2.85 per share, far worse than the $0.55 consensus loss. The result highlights ongoing pre-commercial cash burn and likely contributes to investor caution.
• Negative Sentiment: Long-term earnings outlook was reduced: HC Wainwright cut its FY2026 EPS forecast to a loss of $4.47 from $2.33, FY2027 to a loss of $3.78 from $2.84, and FY2028 to a loss of $2.27 from $1.52. Its FY2029 profit estimate fell to $0.42 from $0.92, while FY2030 declined to $3.41 from $3.73. These revisions suggest profitability may take longer to develop.
• Negative Sentiment: Insider selling adds a modest negative signal: David Malcom Rodman sold 2,170 shares for approximately $58,785, reducing his stake by 4.05%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which limits its signaling value. Mineralys insider sale

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.